Research Summary: The following information is provided for research context only.
This vial combines two complementary growth hormone-releasing compounds: CJC-1295 No DAC and Ipamorelin, each at 5mg for a total of 10mg.
CJC-1295 No DAC is a modified form of growth hormone-releasing hormone (GHRH). In research models it signals pituitary tissue to release growth hormone (GH), and its shorter active window — compared to DAC versions — allows researchers to study more controlled, time-limited GH-release patterns.
Ipamorelin is a selective growth hormone secretagogue that mimics ghrelin. Unlike some other GH-stimulating compounds, it triggers GH release in preclinical models without significantly raising cortisol or prolactin levels, making it a useful tool for studying isolated GH-receptor activity.
When studied together, these two compounds show a synergistic effect in research models — CJC-1295 No DAC amplifies the GH pulse while Ipamorelin governs the timing and selectivity of release. The combination is commonly used in in-vitro research examining the growth hormone axis, GH-secretagogue receptor signaling, and pulsatile-release characterization.
This vial contains lyophilized CJC-1295 No DAC + Ipamorelin at high purity for each peptide, verified by independent, third-party analytical testing.
Structure, CAS and molecular data, mechanism, storage and published literature: see our CJC-1295 No DAC + Ipamorelin research reference.
Reviews
There are no reviews yet.